A group of 38 state attorneys general have submitted a letter to the U.S. Food and Drug Administration (FDA) in response to the agency’s call for comments on possible regulatory approaches for cannabis and cannabis-derived products such as cannabidiol (CBD). “As the primary enforcers of our respective states’ consumer protection laws, we offer a unique perspective as to the new legalized market of certain cannabis and cannabis-derived compounds, including CBD products,” the letter states. “A crucial element of FDA regulation and oversight should be an on-going assessment of the potential risks or benefits of these products, particularly for specific populations such as pregnant women, adolescents and children, and the elderly. How these products interact with other dietary or pharmaceutical products should be included in this assessment. It is also important that companies not mislead consumers. Scientific and medical data from the FDA would assist in meaningful enforcement of advertising laws and regulations by the states.”

The public comment period concluded July 16, 2019, and FDA received nearly 4,000 comments, including from advocacy groups—such as the Center for Science in the Public Interest—and industry groups, including the National Cannabis Industry Association and National Grocers Association.

Shook’s Cannabis Law team partnered with ALM Media for a white paper on the legal landscape for the global cannabis market. Read more >>